問題一覧
1
発癌性
2
遺伝毒性
3
癌(腫)
4
奇形
5
乳房の
6
肝細胞の
7
胃腸の
8
内皮
9
内皮異常増殖
10
前癌性の
11
血管肉腫
12
上方調節
13
The increased incidence of hemangiosarcoma in mice occurred only in organs where this tumour occurs as a relatively common spontaneous finding in the mouse (liver, spleen, uterus etc. )., A study in the mouse demonstrated that vildagliptin inhibits VEGF-induced angiogenes is., Based on these mechanistic data the applicant proposes a mechanism thereby inhibition of VEGF-induced angiogenesis over a long period exerts selection pressure in favour of endothelium that proliferates independently of VEGF and hence increases the likelihood of endothelial neoplasia.
14
There was a disproportionate increase in hemangiosarcoma involving the liver in treated male mice at ≥ 250 mg/kg/day., In the mouse these was an increased incidence of hemangiosarcomas and mammary carcinoma.
15
Life-time carcinogenicity studies were performed in mice and rats., No evidence for a carcinogenic potential was observed in the rat., An increased incidence of hemangiosarcomas was observed at the highest dose in female rats while in male rats, the incidence was slightly decreased., Given the mouse findings discussed below, a relation to treatment cannot be fully excluded., It is suggested that a predisposition to spontaneous hemangiosarcoma at the affected site is needed for vildagliptin to promote an increased incidence.
生理化学Ⅳ 神様仏様
生理化学Ⅳ 神様仏様
サトゥー · 133問 · 3年前生理化学Ⅳ 神様仏様
生理化学Ⅳ 神様仏様
133問 • 3年前感染症学入門 自学
感染症学入門 自学
サトゥー · 197問 · 3年前感染症学入門 自学
感染症学入門 自学
197問 • 3年前薬理学 コリン作動薬/抗コリン作動薬
薬理学 コリン作動薬/抗コリン作動薬
サトゥー · 48問 · 4年前薬理学 コリン作動薬/抗コリン作動薬
薬理学 コリン作動薬/抗コリン作動薬
48問 • 4年前感染症学入門 自学
感染症学入門 自学
サトゥー · 197問 · 3年前感染症学入門 自学
感染症学入門 自学
197問 • 3年前感染症学1
感染症学1
サトゥー · 122問 · 3年前感染症学1
感染症学1
122問 • 3年前生理化学IV
生理化学IV
サトゥー · 93問 · 3年前生理化学IV
生理化学IV
93問 • 3年前生理化学IV
生理化学IV
サトゥー · 93問 · 3年前生理化学IV
生理化学IV
93問 • 3年前薬理学Ⅱ-6 (6/7のテスト内容)
薬理学Ⅱ-6 (6/7のテスト内容)
サトゥー · 38問 · 2年前薬理学Ⅱ-6 (6/7のテスト内容)
薬理学Ⅱ-6 (6/7のテスト内容)
38問 • 2年前薬理学Ⅱ-8 (6/21テスト内容)
薬理学Ⅱ-8 (6/21テスト内容)
サトゥー · 27問 · 2年前薬理学Ⅱ-8 (6/21テスト内容)
薬理学Ⅱ-8 (6/21テスト内容)
27問 • 2年前薬理学Ⅱ-9 (6/28がテスト日)
薬理学Ⅱ-9 (6/28がテスト日)
サトゥー · 44問 · 2年前薬理学Ⅱ-9 (6/28がテスト日)
薬理学Ⅱ-9 (6/28がテスト日)
44問 • 2年前薬理学Ⅱ-10 ( 7/5にテスト日)
薬理学Ⅱ-10 ( 7/5にテスト日)
サトゥー · 39問 · 2年前薬理学Ⅱ-10 ( 7/5にテスト日)
薬理学Ⅱ-10 ( 7/5にテスト日)
39問 • 2年前感染治療学
感染治療学
サトゥー · 43問 · 2年前感染治療学
感染治療学
43問 • 2年前免疫学
免疫学
サトゥー · 5問 · 2年前免疫学
免疫学
5問 • 2年前感染症
感染症
サトゥー · 5問 · 2年前感染症
感染症
5問 • 2年前第三回
第三回
サトゥー · 79問 · 2年前第三回
第三回
79問 • 2年前問題一覧
1
発癌性
2
遺伝毒性
3
癌(腫)
4
奇形
5
乳房の
6
肝細胞の
7
胃腸の
8
内皮
9
内皮異常増殖
10
前癌性の
11
血管肉腫
12
上方調節
13
The increased incidence of hemangiosarcoma in mice occurred only in organs where this tumour occurs as a relatively common spontaneous finding in the mouse (liver, spleen, uterus etc. )., A study in the mouse demonstrated that vildagliptin inhibits VEGF-induced angiogenes is., Based on these mechanistic data the applicant proposes a mechanism thereby inhibition of VEGF-induced angiogenesis over a long period exerts selection pressure in favour of endothelium that proliferates independently of VEGF and hence increases the likelihood of endothelial neoplasia.
14
There was a disproportionate increase in hemangiosarcoma involving the liver in treated male mice at ≥ 250 mg/kg/day., In the mouse these was an increased incidence of hemangiosarcomas and mammary carcinoma.
15
Life-time carcinogenicity studies were performed in mice and rats., No evidence for a carcinogenic potential was observed in the rat., An increased incidence of hemangiosarcomas was observed at the highest dose in female rats while in male rats, the incidence was slightly decreased., Given the mouse findings discussed below, a relation to treatment cannot be fully excluded., It is suggested that a predisposition to spontaneous hemangiosarcoma at the affected site is needed for vildagliptin to promote an increased incidence.